DataVXJournal of Nanoparticle ResearchPaper
journal article·2024-06

Are poly (isobutylcyanoacrylate) nanoparticles a promising nanosystem?

Iago Dillion Lima Cavalcanti, Andreza Tallyne de Aguiar Silva, Vinícius da Silva Maciel, João Lima Tavares, Nereide Stela Santos-Magalhães, Mariane Cajubá de Britto Lira-Nogueira

Journal of Nanoparticle Research· Volume 26· Issue 6
Publisher page
Bibliographic record

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

Nanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Polymer Synthesis and Characterization · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Pimentel LF, Jácome Júnior AT, Mosqueira VCF, Santos-Magalhães NS (2007) Nanotecnologia farmacêutica aplicada ao tratamento da malária. Rev Bras Ciênc Farm 43(4):503–514. https://doi.org/10.1590/S1516-9332200700040000310.1590/S1516-93322007000400003 ↗
2. Prasad M, Lambe UP, Brar B, Shah I, Manimegalai J, Ranjan K et al (2018) Nanotherapeutics: an insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed Pharmacother 97:1521–153710.1016/j.biopha.2017.11.026 ↗
3. Souto EB, Severino P, Santana MHA (2012) Preparação de nanopartículas poliméricas a partir da polimerização de monômeros – Parte I. Polímeros 22(1):96–10010.1590/S0104-14282012005000006 ↗
4. Yadav HK, Almokdad AA, Sumia IM, Debe MS (2019) Chapter 17 - Polymer-based nanomaterials for drug-delivery carriers. In: Nanocarriers for drug delivery. Nanoscience and Nanotechnology in Drug Delivery Micro and Nano Technologies 531–556. https://doi.org/10.1016/B978-0-12-814033-8.00017-510.1016/B978-0-12-814033-8.00017-5 ↗
5. Alexander A, Ajazuddin Patel RJ, Saraf S, Saraf S (2016) Recent expandion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives. J Control Release 241:110–12410.1016/j.jconrel.2016.09.017 ↗
6. Kumar CSSR (2010) Nanotechnology tools in pharmaceutical R&D. Materialstoday 12(Supplement 1):24–30
7. Fornaguera C, Calderó G, Solans C, Vauthier C (2015) Protein-nanoparticle interactions evaluation by immunomethods: surfactants can disturb quantitative determinations. Eur J Pharm Biopharm 94:284–290. https://doi.org/10.1016/j.ejpb.2015.05.02510.1016/j.ejpb.2015.05.025 ↗
8. Oowaki H, Matsuda S, Sakai N, Ohta T, Iwata H, Sadato A et al (2000) Non-adhesive cyanoacrylate as an embolic material for endovascular neurosurgery. Biomaterials 21:1039–1046. https://doi.org/10.1016/s0142-9612(99)00278-110.1016/s0142-9612(99)00278-1 ↗
9. Reece TB, Maxey TS, Kron IL (2001) A prospectus on tissue adhesives. Am J Surg 182:40–44. https://doi.org/10.1016/s0002-9610(01)00742-510.1016/s0002-9610(01)00742-5 ↗
10. Sargi N, Vauthier C, Didierlaurent A, Thao TX, Devissaguet JP, Couvreur P (1994) Adsorption of allergen extracts onto colloidal particles. J Colloid Interface Sci 166(2):294–30110.1006/jcis.1994.1298 ↗
11. Bertholon I, Lesieur S, Labarre D, Besnard M, Vauthier C (2006) Characterization of dextran-poly(isobutylcyanoacrylate) copolymers obtained by redox radical and anionic emulsion polymerization. Macromolecules 39:3559–3567. https://doi.org/10.1021/ma060338z10.1021/ma060338z ↗
12. Lira MCB, Santos-Magalhães NS, Nicolas V, Marsaud V, Silva MPC, Ponchel G, Vauthier C (2011) Cytotoxicity and cellular uptake of newly synthesized fucoidan-coated nanoparticles. Eur J Pharm Biopharm 79(1):162–170. https://doi.org/10.1016/j.ejpb.2011.02.01310.1016/j.ejpb.2011.02.013 ↗
13. Némati F, Dubernet C, Verdière AC, Poupon MF, Treupel-Acar L, Puisieux F, Couvreur P (1994) Some parameters influencing cytotoxicity of free doxorubicin and doxorubicin-loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells: incubation time, number of nanoparticles per cell. Int J Pharm 102(1–3):55–62. https://doi.org/10.1016/0378-5173(94)90039-610.1016/0378-5173(94)90039-6 ↗
14. Chauvierre C, Leclerc L, Labarre D, Appel M, Marden MC, Couvreur P et al (2007) Enhancing the tolerance of poly(isobutylcyanoacrylate) nanoparticles with a modular surface design. Int J Pharm 338:327–332. https://doi.org/10.1016/j.ijpharm.2007.01.03110.1016/j.ijpharm.2007.01.031 ↗
15. Bouchemal K, Ponchel G, Mazzaferro S, Campos-Requena V, Gueutin C, Palmieri GF et al (2008) A new approach to determine loading efficiency of Leu-enkephalin in poly(isobutylcyanoacrylate) nanoparticles coated with thiolated chitosan. J Drug Deliv Sci Technol 18(6):392–397. https://doi.org/10.1016/S1773-2247(08)50077-310.1016/S1773-2247(08)50077-3 ↗
16. Lourenço C, Teixeira M, Simões S, Gaspar R (1996) Steric stabilization of nanoparticles: size and surface properties. Int J Pharm 138(1):1–12. https://doi.org/10.1016/0378-5173(96)04486-910.1016/0378-5173(96)04486-9 ↗
17. Cavalcanti IDL, Ximenes RM, Pessoa ODL, Magalhães NSS, Lira-Nogueira MCB (2021) Fucoidan-coated PIBCA nanoparticles containing oncocalyxone A: activity against metastatic breast cancer cells. J Drug Deliv Sci Technol 65:102698. https://doi.org/10.1016/j.jddst.2021.10269810.1016/j.jddst.2021.102698 ↗
18. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P (1979) Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 31(5):331–33210.1111/j.2042-7158.1979.tb13510.x ↗
19. Huang CH, Chen CM, Lee YD (2009) Synthesis of high loading and encapsulation efficient paclitaxel-loaded poly(n-butil cyanoacrylate) nanoparticles via miniemusion. Int J Pharm 338(1–2):267–27510.1016/j.ijpharm.2007.01.052 ↗
20. Ren F, Chen R, Wang Y, Sun Y, Jiang Y, Li G (2011) Paclitaxel-loaded poly(n-butilcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer. Pharm Res 28:897–906. https://doi.org/10.1007/s11095-010-0346-910.1007/s11095-010-0346-9 ↗
21. Behan N, Birkinshaw C, Clarke N (2001) Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerization and particle formation. Biomaterials 22(11):1335–1344. https://doi.org/10.1016/S0142-9612(00)00286-610.1016/S0142-9612(00)00286-6 ↗
22. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P (2003) Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 55(4):519–548. https://doi.org/10.1016/S0169-409X(03)00041-310.1016/S0169-409X(03)00041-3 ↗
23. Hillaireau H, Couvreur P (2009) Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66(17):2873–2896. https://doi.org/10.1007/s00018-009-0053-z10.1007/s00018-009-0053-z ↗
24. Lenaerts V, Couvreur P, Christiaens-Leyh D, Joiris E, Roland M, Rollman B, Speiser P (1984) Degradation of poly (isobutylcyanoacrylate) nanoparticles. Biomaterials 5:65–68. https://doi.org/10.1016/0142-9612(84)90002-410.1016/0142-9612(84)90002-4 ↗
25. Gallardo M, Couarraze G, Denizot B, Treupel L, Couvreur P, Puisieux F (1993) Study of the mechanisms of formation of nanoparticles and nanocapsules of polyisobutyl-2-cyanoacrylate. Int J Pharm 100(1–3):55–64. https://doi.org/10.1016/0378-5173(93)90075-Q10.1016/0378-5173(93)90075-Q ↗
26. Peracchia MT, Vauthier C, Passirani C, Couvreur P, Labarre D (1997) Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci 61(7):749–761. https://doi.org/10.1016/s0024-3205(97)00539-010.1016/s0024-3205(97)00539-0 ↗
27. Sarfraz M, Roa W, Bou-Chacra N, Lobenber R (2016) Inflammation caused by nanosized delivery systems: is there a benefit? Mol Pharm 13(9):3270–3278. https://doi.org/10.1021/acs.molpharmaceut.6b0053010.1021/acs.molpharmaceut.6b00530 ↗
28. Al-Hallak MHDK, Sarfraz MK, Azarmi S, Kohan MHG, Roa WH, Lobenberg R (2011) Microcalorimetric method to assess phagocytosis: macrophage-nanoparticle interactions. AAPS J 13:20–29. https://doi.org/10.1208/s12248-010-9240-y10.1208/s12248-010-9240-y ↗
29. Peracchia MT, Vauthier C, Puisieux F, Couvreur P (1997) Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol). J Biomed Mater Res 34:317–326. https://doi.org/10.1002/(SICI)1097-4636(19970305)34:3%3c317::AID-JBM6%3e3.0.0CO;2-N10.1002/(SICI)1097-4636(19970305)34:3<317::AID-JBM6>3.0.0CO;2-N ↗
30. Martins MBF, Simões SID, Crus MEM, Gaspar R (1996) Development of enzyme-loaded nanoparticles: effect of pH. J Mater Sci - Mater Med 7:413–414. https://doi.org/10.1007/BF0012201010.1007/BF00122010 ↗
31. Fernández-Urrusuno R, Fattal E, Rodrigues JM, Féger J, Bedossa P, Couvreur P (1996) Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J Biomed Mater Res 31:401–408. https://doi.org/10.1002/(SICI)1097-4636(199607)31:3%3c401::AID/JBM15%3e3.0.CO;2-L10.1002/(SICI)1097-4636(199607)31:3<401::AID/JBM15>3.0.CO;2-L ↗
32. Nakada Y, Fattal E, Foulquier M, Couvreur P (1996) Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm Res 13:38–43. https://doi.org/10.1023/A:101601701457310.1023/A:1016017014573 ↗
33. Verdière AC, Dubernet C, Nemati F, Poupon MF, Puisieux F, Couvreur P (1994) Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother Pharmacol 33:504–50810.1007/BF00686509 ↗
34. Gibaud S, Andreux JP, Weingarten C, Renard M, Couvreur P (1994) Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur J Cancer 30A(6):820–826. https://doi.org/10.1016/0959-8049(94)90299-210.1016/0959-8049(94)90299-2 ↗
35. Lambert G, Fattal E, Brehier A, Feger J, Couvreur P (1998) Effect of polyisobutylcyanoacrylate nanoparticles and Lipofectin® loaded with oligonucleotides on cell viability and PKCα neosynthesis in HepG2 cells. Biochimie 80(12):969–976. https://doi.org/10.1016/S0300-9084(99)80002-910.1016/S0300-9084(99)80002-9 ↗
36. Martins MBF, Simões SID, Supico A, Cruz MEM, Gaspar R (1996) Enzyme-loaded PIBCA nanoparticles (SOD and L-ASNase): optimization and characterization. Int J Pharm 142(1):75–84. https://doi.org/10.1016/0378-5173(96)04652-210.1016/0378-5173(96)04652-2 ↗
37. Olivier JC, Vauthier C, Taverna M, Puisieux F, Ferrier D, Couvreur P (1996) Stability of orosomucoid-coated polyisobutylcyanoacrylate nanoparticles in the presence of serum. J Control Release 40(3):157–168. https://doi.org/10.1016/0168-3659(95)00175-110.1016/0168-3659(95)00175-1 ↗
38. Radwan MA, Zaghloul IY, Aly ZH (1999) In vivo performance of parenteral theophylline-loaded polyisobutylcyanoacrylate nanoparticles in rats. Eur J Pharm Sci 8(2):95–98. https://doi.org/10.1016/s0928-0987(98)00060-810.1016/s0928-0987(98)00060-8 ↗
39. Brasseur N, Brault D, Couvreur P (1991) Adsorption of hematoporphyrin onto polyalkylcyanoacrylate nanoparticles: carrier capacity and drug release. Int J Pharm 70(1–2):129–135. https://doi.org/10.1016/0378-5173(91)90172-K10.1016/0378-5173(91)90172-K ↗
40. Fernández-Urrusuno R, Fattal E, Féger J, Couvreur P, Thérond P (1997) Evaluation of hepatic antioxidant systems after intravenous administration of polymeric nanoparticles. Biomaterials 18(6):511–517. https://doi.org/10.1016/S0142-9612(96)00178-010.1016/S0142-9612(96)00178-0 ↗
41. Coty JB, Oliveira EE, Vauthier C (2017) Tuning complement activation and pathway through controlled molecular architecture of dextran chains in nanoparticle corona. Int J Pharm 532(2):769–778. https://doi.org/10.1016/j.ijpharm.2017.04.04810.1016/j.ijpharm.2017.04.048 ↗
42. Olivier JC, Vauthier C, Taverna M, Ferrier D, Couvreur P (1995) Preparation and characterization of biodegradable poly(isobutylcyano acrylate) nanoparticles with the surface modified by the adsorption of proteins. Colloids Surf B 4:349–356. https://doi.org/10.1016/0927-7765(95)01187-N10.1016/0927-7765(95)01187-N ↗
43. Fawaz F, Guyot M, Lagueny AM, Devissaguet J (1997) Ciproflexacin-loaded polyisobutylcyanoacrylate nanoparticles: preparation and characterization. Int J Pharm 154(2):191–20310.1016/S0378-5173(97)00138-5 ↗
44. Fawaz F, Bonini F, Maugein J, Lagueny AM (1998) Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial. Int J Pharm 168(2):255–259. https://doi.org/10.1016/S0378-5173(98)00116-110.1016/S0378-5173(98)00116-1 ↗
45. Couvreur P, Kante B, Grislain L, Roland M, Speiser P (1982) Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J Pharm Sci 71(7):790–792. https://doi.org/10.1002/jps.260071071710.1002/jps.2600710717 ↗
46. Tang Z, He C, Tian H, Ding J, Hsiao BS, Chu B et al (2016) Polymeric nanostructured materials for biomedical applications. Prog Polym Sci 60:86–128. https://doi.org/10.1016/j.progpolymsci.2016.05.00510.1016/j.progpolymsci.2016.05.005 ↗
47. Zandanel C, Vauthier C (2012) Characterization of fluorescent poly(isobutylcyanoacrylate) nanoparticles obtained by copolymerization of a fluorescent probe during redox radical emulsion polymerization (RREP). Eur J Pharm Biopharm 82(1):66–75. https://doi.org/10.1016/j.ejpb.2012.05.00210.1016/j.ejpb.2012.05.002 ↗
48. Antunes JC, Benarroch L, Moraes FC, Juenet M, Gross MS, Aubart M et al (2019) Core-shell polymer-based nanoparticles deliver miR-155-5p to endothelial cells. Mol Ther Nucleic Acids 17:210–222. https://doi.org/10.1016/j.omtn.2019.05.01610.1016/j.omtn.2019.05.016 ↗
49. Hillaireau H, Le Doan T, Chacun H, Janin J, Couvreur P (2007) Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. Int J Pharm 331:148–152. https://doi.org/10.1016/j.ijpharm.2006.10.03110.1016/j.ijpharm.2006.10.031 ↗
50. Vauthier C (2019) A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles. J Drug Target 27(5–6):502–524. https://doi.org/10.1080/1061186X.2019.158828010.1080/1061186X.2019.1588280 ↗
51. Varenne F, Devoille L, Makky A, Feltin N, Violleau F, Barratt G, Vauthier C (2020) Evaluation of the size distribution of a multimodal dispersion of polymer nanoparticles by microscopy after different methods of deposition. J Drug Deliv Sci Technol 60:102047. https://doi.org/10.1016/j.jddst.2020.10204710.1016/j.jddst.2020.102047 ↗
52. Chauvierre C, Labarre D, Couvreur P, Vauthier C (2003) Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm Res 20:1786–179310.1023/B:PHAM.0000003376.57954.2a ↗
53. Bertholon-Rajot I, Labarre D, Vauthier C (2005) Influence of the initiator system, cerium-polysaccharide, on the surface properties of poly(isobutylcyanoacrylate) nanoparticles. Polymer 46(4):1407–141510.1016/j.polymer.2004.11.067 ↗
54. Pradines B, Djabourov M, Vauthier C, Loiseau PM, Ponchel G, Bouchemal K (2015) Gelatin and micellization behaviors of pluronic® F127 hydrogel containing poly(isobutylcyanoacrylate) nanoparticles specifically designed for mucosal application. Colloids Surf B 135:669–676. https://doi.org/10.1016/j.colsurfb.2015.08.02110.1016/j.colsurfb.2015.08.021 ↗
55. Palazzo C, Trapani G, Ponchel G, Trapani A, Vauthier C (2017) Mucoadhesive properties of low molecular weight chitosan - or glycol chitosan - and corresponding thiomer-coated poly(isobutylcyanoacrylate) coreshell nanoparticles. Eur J Pharm Biopharm 117:315–323. https://doi.org/10.1016/j.ejpb.2017.04.02010.1016/j.ejpb.2017.04.020 ↗
56. Bravo-Osuna I, Millotti G, Vauthier C, Ponchel G (2007) In vitro evaluation of calcium binding capacity of chitosan and thiolated chitosan poly(isobutyl cyanoacrylate) core-shell nanoparticles. Int J Pharm 338:284–290. https://doi.org/10.1016/j.ijpharm.2007.01.03910.1016/j.ijpharm.2007.01.039 ↗
57. Bravo-Osuna I, Vauthier C, Farabollini A, Palmieri GF, Ponchel G (2007) Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 28:2233–2243. https://doi.org/10.1016/j.biomaterials.2007.01.00510.1016/j.biomaterials.2007.01.005 ↗
58. Bravo-Osuna I, Vauthier C, Chacun H, Ponchel G (2008) Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutylcyanoacrylate) core-shell nanoparticles. Eur J Pharm Biopharm 69:436–444. https://doi.org/10.1016/j.ejpb.2007.12.01210.1016/j.ejpb.2007.12.012 ↗
59. Varenne F, Hillaireau H, Bataille J, Smadja C, Barratt G, Vauthier C (2019) Application of validated protocols to characterize size and zeta potential of dispersed materials using light scattering methods. Colloids Surf A 560:418–425. https://doi.org/10.1016/j.colsurfa.2018.09.00610.1016/j.colsurfa.2018.09.006 ↗
60. Fallouh NAK, Roblot-Treupel L, Fessi H, Devissaguet J, Puisieux F (1986) Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int J Pharm 28(2–3):125–132. https://doi.org/10.1016/0378-5173(86)90236-X10.1016/0378-5173(86)90236-X ↗
61. Layre AM, Couvreur P, Richard J, Requier D, Eddine Ghermani N, Gref R (2006) Freeze-drying of composite core-shell nanoparticles. Drug Dev Ind Pharm 32:839–84610.1080/03639040600685134 ↗
62. Layre A, Couvreur P, Chacun H, Richard J, Passirani C, Requier D et al (2006) Novel composite core-shell nanoparticles as busulfan carriers. J Control Release 111:271–28010.1016/j.jconrel.2006.01.002 ↗
63. Wasiak I, Kulikowska A, Janczewska M, Michalak M, Cymerman IA, Nagalski A, Kallinger P, Szymanski WW, Ciach T (2016) Dextran nanoparticle synthesis and properties. PLoS One 11(1). https://doi.org/10.1371/journal.pone.014623710.1371/journal.pone.0146237 ↗
64. Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women: FGF23 in iron deficiency. J Bone Miner Res 28:1793–1803. https://doi.org/10.1002/jbmr.192310.1002/jbmr.1923 ↗
65. Fedele F (2003) DEAE-dextran in the treatment of primary hypercholesterolemia and/or hypercholesterolemia combined with hypertriglyceridemia. A multicentric randomized study on the efficacy of DEAE-dextran compared with cholestyramine. Clin Ther 154(4):231–236
66. Anitha A, Deepagan VG, Divya Rani VV, Menon D, Nair SV, Jayakumar R (2011) Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohyd Polym 84:1158–1164. https://doi.org/10.1016/j.carbpol.2011.01.00510.1016/j.carbpol.2011.01.005 ↗
67. Alhareth K, Vauthier C, Bourasset F, Gueutin C, Ponchel G, Moussa F (2012) Conformation of surface-decorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles. Eur J Pharm Biopharm 81:453–457. https://doi.org/10.1016/j.ejpb.2012.03.00910.1016/j.ejpb.2012.03.009 ↗
68. Gibaud S, Rousseau C, Weingarten C, Favier R, Douay L, Andreux JP, Couvreur P (1998) Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). J Control Release 52(1–2):131–13910.1016/S0168-3659(97)00194-6 ↗
69. Vauthier C, Cabane B, Labarre D (2008) How to concentrate nanoparticles and avoid aggregation? Eur J Pharm Biopharm 69(2):466–475. https://doi.org/10.1016/j.ejpb.2008.01.02510.1016/j.ejpb.2008.01.025 ↗
70. Amaral CCF, Pacheco BS, Seixas FK, Pereira CMP, Collares T (2020) Antitumoral effects of fucoidan on bladder cancer. Algal Res 47:101884. https://doi.org/10.1016/j.algal.2020.10188410.1016/j.algal.2020.101884 ↗
71. Silva VAJ, Andrade PL, Silva MPC, Bustamante DA, Valladares LLS, Aguiar JA (2013) Synthesis and characterization of Fe3O4 nanoparticles coated with fucan polysaccharides. J Magn Magn Mater 343:138–143. https://doi.org/10.1016/j.jmmm.2013.04.06210.1016/j.jmmm.2013.04.062 ↗
72. Tsai L, Chen C, Lin C, Ho Y, Mi F (2019) Development of mutlifunctional nanoparticles self-assembled from trimethyl chitosan and fucoidan for enhanced oral delivery of insulin. Int J Biol Macromol 126:141–150. https://doi.org/10.1016/j.ijbiomac.2018.12.18210.1016/j.ijbiomac.2018.12.182 ↗
73. Etman SM, Elnaggar YSR, Abdallah OY (2020) Fucoidan, a natural biopolymer in cancer combating: from edible algae to nanocarrier tailoring. Int J Biol Macromol 147:799–808. https://doi.org/10.1016/j.ijbiomac.2019.11.19110.1016/j.ijbiomac.2019.11.191 ↗
74. Li B, Juenet M, Aid-Launais R, Maire M, Ollivier V, Letourneur D et al (2017) Development of polymer microcapsules functionalized with fucoidan to target P-selectin overexpressed in cardiovascular diseases. Adv Healthcare Mater. https://doi.org/10.1002/adhm.20160120010.1002/adhm.201601200 ↗
75. Li B, Aid-Launais R, Laboura M, Zenycha A, Jueneta M, Choqueuxa C et al (2019) Functionalized polymer microbubbles as new molecular ultrasound contrast agent to target P-selectin in thrombus. Biomaterials 194:139–150. https://doi.org/10.1016/j.biomaterials.2018.12.02310.1016/j.biomaterials.2018.12.023 ↗
76. Lira-Nogueira MCB, Gibson VP, Nicolas V, Santos-Magalhães NS, Vauthier C (2022) Defining endocytic pathways of fucoidan-coated PIBCA nanoparticles from the design of their surface architecture. Pharm Res. https://doi.org/10.1007/s11095-022-03202-410.1007/s11095-022-03202-4 ↗
77. Cheung RCF, Ng TB, Wong JH, Chan WY (2015) Chitosan: an update on potential biomedical and pharmaceutical applications. Mar Drugs 13(8):5156–5186. https://doi.org/10.3390/md1308515610.3390/md13085156 ↗
78. Merzendorfer H, Cohen E (2019) Chitin/chitosan: versatile ecological, industrial, and biomedical applications. In: Cohen E, Merzendorfer H (eds) Extracellular sugar-based biopolymers matrices Biologically-inspired systems, v.12. Springer, Cham. https://doi.org/10.1007/978-3-030-12919-4_1410.1007/978-3-030-12919-4_14 ↗
79. Bravo-Osuna I, Schmitz T, Bernkop-Schnurch A, Vauthier C, Ponchel G (2006) Elaboration and characterization of thiolated chitosan-coated acrylic nanoparticles. Int J Pharm 316(1–2):170–17510.1016/j.ijpharm.2006.02.037 ↗
80. Bravo-Osuna I, Ponchel G, Vauthier C (2007) Tuning of shell and core characteristics of chitosan-decorated acrylic nanoparticles. Eur J Pharm Sci 30:143–15410.1016/j.ejps.2006.10.007 ↗
81. Bravo-Osuna I, Teutonico D, Arpicco S, Vauthier C, Ponchel G (2007) Characterization of chitosan thiolation and application to thiol quantification onto nanoparticle surface. Int J Pharm 340(1–2):173–18110.1016/j.ijpharm.2007.03.019 ↗
82. Malli S, Pomel S, Ayadi Y, Delomenie C, Costa A, Loiseau PM et al (2019) Topically applied chitosan-coated poly(isobutylcyanoacrylate) nanoparticles are active against cutaneous leishmaniasis by accelerating lesion healing and reducing the parasitic load. ACS Appl Bio Mater 2(6):2573–2586. https://doi.org/10.1021/acsabm.9b0026310.1021/acsabm.9b00263 ↗
83. Atyabi F, Moghaddam FA, Dinarvand R, Zohuriaan-Mehr MJ, Ponchel G (2008) Thiolated chitosan coated poly hydroxyethyl methacrylate nanoparticles: synthesis and characterization. Carbohyd Polym 74(1):59–6710.1016/j.carbpol.2008.01.015 ↗
84. Mazzaferro S, Bouchemal K, Skanji R, Gueutin C, Chacun H, Ponchel G (2012) Intestinal permeation enhancement of docetaxel encapsulated into methyl-β-cyclodextrin/poly(isobutylcyanoacrylate) nanoparticles coated with thiolated chitosan. J Control Release 162(3):568–574. https://doi.org/10.1016/j.jconrel.2012.08.00510.1016/j.jconrel.2012.08.005 ↗
85. Sampaio LO, Tersariol ILS, Lopes CC, Bouças RI, Nascimento FD, Rocha HAO et al (2006) Heparins and heparan sulfates. Structure, distribution and protein interactions. Insights into carbohydrate structure and biological function.Transworld Research Network, Kerala, pp 51–61
86. Dreyfuss JL, Regatieri CV, Jarrouge TR, Cavalheiro RP, Sampaio LO, Nader HB (2009) Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. An Acad Bras Ciênc 81(3):409–429. https://doi.org/10.1590/S0001-3765200900030000710.1590/S0001-37652009000300007 ↗
87. Shriver Z, Capilla I, Venkataraman G, Sasisekharan R (2012) Heparin and heparan sulfate: analyzing structure and microheterogeneity. Handb Exp Pharmacol 207:159–176. https://doi.org/10.1007/978-3-642-23056-1_810.1007/978-3-642-23056-1_8 ↗
88. Jannati M, Ardecani AA (2020) Prevention of pulmonary and venous thromboembolism post coronary artery bypass graft surgery - literature review. Braz J Cardiovasc Surg 35(3). https://doi.org/10.21470/1678-9741-2018-034510.21470/1678-9741-2018-0345 ↗
89. Makaryus JN, Lau JF (2013) Advances in the medical management of venous thromboembolism. Endovasc Today 33–47.
90. Thaler J, Pabinger I, Ay C (2015) Anticoagulant treatment of deep vein thrombosis and pulmonary embolism: the present state of the art. Front Cardiovasc Med 2. https://doi.org/10.3389/fcvm.2015.0003010.3389/fcvm.2015.00030 ↗
91. Chauvierre C, Marden MC, Vauthier C, Labarre D, Couvreur P, Leclerc L (2004) Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin/ a new oxygen carrier. Biomaterials 25(15):3081–3086. https://doi.org/10.1016/j.biomaterials.2003.09.09710.1016/j.biomaterials.2003.09.097 ↗
92. Silva ATA, Cavalcanti IDL, Sobral MA, Lima GMS, Pessoa ODL, Magalhães NSS, Coimbra CGO (2023) Development of levan-coated PIBCA nanoparticles and their antiproliferative activity against MDA-MB-231 and B16F10 cells. Colloids Surf A 670:131567. https://doi.org/10.1016/j.colsurfa.2023.13156710.1016/j.colsurfa.2023.131567 ↗
93. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM (2016) PEGylation as a strategy for improving nanoparticles-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51. https://doi.org/10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
94. Boudad H, Legrand P, Lebas G, Cheron M, Duchêne D, Ponchel G (2001) Combined hydroxypropyl-ß-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm 218(1–2):113–12410.1016/S0378-5173(01)00622-6 ↗
95. Vauthier C, Bouchemal K (2009) Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 26(5):1025–1058. https://doi.org/10.1007/s11095-008-9800-310.1007/s11095-008-9800-3 ↗
96. Vauthier C, Persson B, Lindner P, Cabane B (2011) Protein adsorption and complement activation for di-block copolymer nanoparticles. Biomaterials 32(6):1646–1656. https://doi.org/10.1016/j.biomaterials.2010.10.02610.1016/j.biomaterials.2010.10.026 ↗
97. Labarre D, Vauthier C, Chauvierre C, Petri B, Müller R, Chehimi MM (2005) Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 26:5075–508410.1016/j.biomaterials.2005.01.019 ↗
98. Pitto-Barry A, Barry NPE (2014) Pluronic® block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances. Polym Chem 5:3291–3297. https://doi.org/10.1039/C4PY00039K10.1039/C4PY00039K ↗
99. Malli S, Bories C, Bourge M, Loiseau PM, Bouchemal K (2018) Surface-dependent endocytosis of poly(isobutylcyanoacrylate) nanoparticles by Trichomonas vaginalis. Int J Pharm 548(1):276–287. https://doi.org/10.1016/j.ijpharm.2018.07.00610.1016/j.ijpharm.2018.07.006 ↗
100. Hillaireau H, Le Doan T, Appel M, Couvreur P (2006) Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J Control Release 116(3):346–35210.1016/j.jconrel.2006.09.016 ↗